In this issue:

• Introduction
• Management of Iron Overload in the Myelodysplastic Syndromes
• Evaluation of Iron Levels to Avoid the Clinical Sequelae of IronOverload
  Taher A, Nathan D, Porter J. Semin Hematol. 2007;44:S2–S6.
• Red Blood Cell Transfusions and Iron Overload in the Treatment of Patients With Myelodysplastic Syndromes
  Jabbour E, Kantarjian HM, Koller C, Taher A. Cancer. 2008; 112:1089–1095.
• Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making
  Malcovati L, Della Porta MG, Pascutto C, et al. J Clin Oncol. 2005;23:7594–7603.
• Current Treatment Options for MDS
  Garcia-Manero G, Yang AS, Jagasia M. Clin Adv Hematol. Oncol. 2007;5:1–9.
• Retrospective Nationwide Survey of Japanese Patients with Transfusion-Dependent MDS and Aplastic Anemia Highlights the Negative Impact of Iron Overload on Morbidity/Mortality
  Takatoku M, Uchiyama T, Okamoto S, et al. Eur J Haematol. 2007;7:487–494.